Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12788/jhm.3587 | DOI Listing |
Nutrients
November 2024
Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, 84081 Baronissi, Italy.
Before metabolic and bariatric surgery (MBS), moderate weight loss and liver left lateral section (LLLS) volume reduction are desirable. Low-carb ketogenic diet-induced weight loss before MBS has been shown to have beneficial effects on the reduction in body weight (BW) and LLLS. However, the nutritional protocol of low-carb ketogenic diet may be hard to keep for prolonged periods due to the lack of sweet taste.
View Article and Find Full Text PDFJAMA Dermatol
December 2024
Department of Dermatology, University of Utah School of Medicine, Salt Lake City.
Dermatol Ther (Heidelb)
October 2024
CorEvitas, LLC, Waltham, MA, USA.
Introduction: Due to variable psoriasis symptoms, disease progression, and individual responses to therapy, patients may start, stop, or switch biologic therapies. Real-world data on the associated disease burden of patients with psoriasis who do and do not switch biologics are incomplete.
Methods: This study compared disease burden among patients from the CorEvitas Psoriasis Registry (July 2017-December 2021) who switched biologics and those who did not within 4-12 months following initiation.
Ultraschall Med
August 2024
Imaging Department, Reproductive & Genetic Hospital of CITIC-Xiangya, Changsha City, China.
J Dermatolog Treat
December 2024
Oregon Medical Research Center, Portland, OR, USA.
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of response in patients randomized to deucravacitinib and placebo only.
Methods: Adults with moderate to severe plaque psoriasis at baseline were randomized 1:2:1 to oral placebo, deucravacitinib, or apremilast.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!